Adam Morgan insider trades: Heron Therapeutics (HRTX) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Adam reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 8, 2025 | HRTX | ↑ Buy | 1,766,546 | $1.50 | $2.6M | By Velan Capital Master Fund LP | Aug 12, 2025 (4d) |
| Feb 8, 2024 | JSPR | ↑ Buy | 350,000 | $12.95 | $4.5M | By Velan Capital Master Fund LP | Feb 9, 2024 (1d) |
| Jul 21, 2023 | HRTX | ↑ Buy | 2,486,744 | $1.37 | $3.4M | By Velan Capital Master Fund LP | Jul 25, 2023 (4d) |
| May 17, 2023 | ALIM | ↑ Buy | 1,401,901 | $1.70 | $2.4M | By Velan Capital Master Fund LP | May 19, 2023 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Adam Morgan's insider trades
Adam Morgan is a director at Heron Therapeutics (HRTX). Since May 17, 2023, Adam has reported 4 open-market purchases worth $13.0M and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (5 filings), other transactions (3 filings), shares returned to the company (1 filing), conversions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every HRTX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.